CurrentUnitedHealthcarePolicy CS379.A

Respiratory Pathogen Nucleic Acid Detection Testing

Defines UnitedHealthcare's medical policy for respiratory pathogen nucleic acid detection testing, excluding certain states where state-specific policies apply; specifies that outpatient respiratory pathogen panel testing of six or more targets is unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyRespiratory Pathogen Nucleic Acid Detection Testing

Policy CodePolicy CS379.A

Change TypeNew Medical Policy

Effective DateFeb 1, 2026

Next Review Date

Key ActionFor outpatient respiratory pathogen panel testing with six or more targets, anticipate denial as not medically necessary based on insufficient evidence unless state/contract requirements override; obtain prior authorization or check benefit terms when applicable.

POLICY UPDATE CHANGES

New Medical Policy created.

>=6 targetsPanel size deemed not medically necessary (outpatient)

11States with state-specific policy listed

9CPT/HCPCS/PLA codes listed

Coverage Summary

Policy CS379.A (Respiratory Pathogen Nucleic Acid Detection Testing) defines UnitedHealthcare's coverage for nucleic acid detection of respiratory pathogens. The policy is effective 02/01/2026. This policy applies broadly but excludes certain states where state-specific policies govern (see application list).

Medical Necessity Criteria

Coverage Rationale

Covered when ALL of the following are met:

ALL of the following

Respiratory pathogen panel testing of six or more targets in an outpatient setting>= 6 targets
Clinical context: outpatient setting
Evidence: insufficient evidence of efficacy for all indications
Conclusion: considered unproven and not medically necessary

ref_diff_marker__doc_x_path_7b5f5f05_0_235_ref_b1_0__ref__ref_b1_0__ref__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0

ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0__ref_b1_0

Coding

Multiplex respiratory pathogen panel CPT/HCPCS codes referencedmixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including SARS-CoV-2, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Provider Actions

Prior Authorization

Prior authorization / coverage determination

For outpatient respiratory pathogen panel testing with six or more targets, obtain prior authorization or a coverage determination before ordering. Anticipate denial as not medically necessary based on insufficient evidence unless state or contract requirements override; check benefit terms when applicable.

Anticipate denial as not medically necessary for outpatient panels >=6 targets unless state/contract overrides

Documentation Required

State application check

Verify whether this UnitedHealthcare Medical Policy applies in the patient's state; if the document lists a state-specific policy, follow that state's policy instead.

Idaho
Indiana
Kansas
Kentucky
Louisiana
Nebraska
New Jersey
New Mexico
North Carolina
Ohio
Pennsylvania
Tennessee

Documentation Required

Clinical justification for multiplex testing

Document the clinical rationale when ordering multiplex respiratory pathogen panels. Note guideline-identified appropriate candidate populations to support testing decisions.

Immunocompromised patients
Hospitalized patients with severe community-acquired pneumonia (severe CAP)
Intensive care unit (ICU) patients
Transplant patients
Oncology (hematology/oncology) patients

Background and Evidence

Multiplex respiratory pathogen panels (NAAT/PCR) detect multiple viral and bacterial targets from a single specimen and provide faster turnaround than culture. Evidence quality for large multiplex outpatient panels is low.

Limitations include interpretation challenges from prolonged viral shedding, the possibility of coinfection or multiple positive results, detection of colonization rather than active infection, and variable accuracy across different targets on the panels.

Evidence summary

Policy clinical conclusionInsufficient evidence to support use of respiratory pathogen panel testing of six or more targets in outpatient setting

Key guideline recommendationsASM/ATS/IDSA suggest targeted use: immunocompromised, ICU, transplant, oncology, severe CAP; routine outpatient testing for non-influenza viruses is not recommended

Respiratory pathogen panel (RPP): Multiplex nucleic acid amplification test that detects multiple respiratory viral and/or bacterial targets from a single specimen; panels vary by number and type of targets.

Outpatient setting: Non-hospitalized patient encounters such as clinics, urgent care, and emergency department visits managed as outpatient.

OpenPayer